https://www.selleckchem.com/pr....oducts/vps34-inhibit
2%) met predefined criteria for SEA; of SEA patients, 72/162 (44.4%) had used HD ICS. SEA and HD ICS SEA patients experienced more clinically significant exacerbations than general asthma patients (1.6 ± 3.3 and 1.5 ± 2.6 vs 0.6 ± 2.0, p 0.01). HD ICS SEA and SEA patients incurred at least 2-2.5-fold higher total asthma-related and all-cause costs than general asthma patients and had significantly greater HCRU. Of eligible Taiwanese general asthma patients, 6.2% met predefined SEA criteria. Compared with general asthma pa
Like
Comment
Share
